Background Regular screening of cirrhotic patients for hepatocellular carcinoma (HCC) has been suboptimal, but there is little data regarding specific risk factors for reduced screening.
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality worldwide [1] . Modern cohort studies have shown that HCC is now the leading cause of death in patients with cirrhosis [2] [3] [4] . Historically, HCC has been most associated with hepatitis B (HBV) and C infection as well as chronic alcohol use, and in the past 30 years, the incidence of HCC in the United States has almost doubled owing mostly to increases in hepatitis C infection (HCV) [5] . However, in recent years, and particularly in the United States, the number of patients with non-alcoholic fatty liver disease (NAFLD) leading to nonalcoholic steatohepatitis (NASH) and cirrhosis has also contributed to the increasing incidence of HCC [6] .
Survival for symptomatic HCC is very poor, with a mean survival at 1 year of *20% and 5-year survival\5% [7] . However, when diagnosed early and treated with surgical or ablative therapy, prognosis is improved, with 3-year survival rates of 60-80% and 5-year survival rates of 40-70% [8] . For this reason, HCC screening is recommended and has been shown to reduce mortality as much as 37% in one study [9] .
The AASLD practice guidelines in 2005 recommended screening for HCC with abdominal imaging every 6-12 months with or without alpha-fetoprotein (AFP) measurement [10] . More recently, in 2010, the recommendation was modified to include abdominal imaging every 6 months [11] . Despite these recommendations, however, screening rates remain low, with rates varying from *50% to lower than 20% [12] [13] [14] . Low screening rates have been linked to delayed tumor detection, larger tumors at diagnosis, and reduced therapeutic options [15] .
Although a number of studies have documented low rates of screening, it is unclear whether or how HCC screening varies by etiology of cirrhosis, practice type, or involvement of specialists. Therefore, we performed a retrospective cohort study designed to examine patient and provider characteristics affecting HCC screening in cirrhotics followed in primary care and gastroenterology outpatient practices.
Methods
Patients diagnosed with cirrhosis between the years of 1996 and 2010 were retrospectively identified from gastroenterology and primary care practices at our institution and affiliated sites. Patients were selected using an ICD-9 code diagnosis of cirrhosis from an institutional research database and from primary care and gastroenterology practices. The Research Patient Data Registry, which is a registry of all patients in the Partners Healthcare system, was searched using the search terms ''liver biopsy'' and ''cirrhosis,'' from which all patients from our institution and affiliated sites with cirrhosis were selected. Similarly, primary care practices were searched specifically using a research database with the search term ''cirrhosis,'' from which all patients with a cirrhosis diagnosis were selected. Patients from gastroenterology practices with an ICD-9 code diagnosis of cirrhosis were selected using medical record numbers, which were not tied to other diagnoses. Cirrhosis diagnoses were verified by review of biopsy histology, imaging studies consistent with a cirrhotic liver, or review of the medical record for evidence of portal hypertension and liver synthetic dysfunction. Patients were eligible if they were older than 18 at the time of cirrhosis diagnosis.
Data was collected from the first diagnosis of cirrhosis or first evidence of cirrhosis in the medical record until the time of (1) a lesion suspicious for HCC noted on imaging or elevated AFP (AFP greater than 20 ng/ml), (2) death, (3) liver transplantation, or (4) end of the data collection period. If patients were lost to follow-up, data collection ended at the date of the last patient encounter. Patients were excluded if they carried a pre-existing diagnosis of HCC, had a lesion suspicious for HCC or elevated AFP on initial screening for HCC, or if they had already undergone liver transplantation. The following patient data were also obtained from the medical record: age, sex, race, etiology of cirrhosis as noted in biopsy reports or physician notes, documentation of gastrointestinal subspecialty clinic visits, and insurance status. Patients were considered to have regular gastroenterology/ hepatology follow-up if they had at least one documented clinic visit per year.
Recommended screening was defined as abdominal imaging (ultrasound or contrast-enhanced CT or MRI) with or without serum AFP measurement at least once every 12 months as indicated by the 2005 AASLD guidelines [10] . All radiographic imaging was reviewed and reported by an attending radiologist. A diagnosis of HCC required biopsy confirmation or lesions on radiology that prompted empiric treatment with either transcatheter arterial chemoembolization or percutaneous radiofrequency ablation.
Statistical analysis was performed using Microsoft Excel 2004 version 11.6 and Stata software version 11.0 (Statacorp, College Station, TX, USA). Categorical variables were analyzed using the Chi-square test. Multivariate analysis was done by multiple logistic regression to evaluate patient and provider characteristics affecting HCC screening. P values \ 0.05 were considered statistically significant. This study was approved by the Partners Healthcare Human Research Committee. . The data collection period ended because of death in six patients, suspicious imaging in 13, elevated AFP in one, both suspicious imaging and elevated AFP in four, liver transplantation in 13, and end of the data collection period in 119 patients. Cirrhosis was diagnosed based on biopsy data in 59% of patients, imaging consistent with cirrhosis in 40%, and solely on clinical features in 1%. Cirrhosis etiologies were viral hepatitis (n = 65 with 17 HBV, 45 HCV, and three HBV and HCV), alcohol (n = 40), non-alcoholic steatohepatitis (NASH) (n = 27), and non-viral, non-alcoholic, non-NASH cirrhosis (n = 24) (see Table 1 ). Sixty-three percent of patients were seen regularly by gastroenterologists or hepatologists and 37% by internists or surgeons alone. Of the 156 patients, 51% received the recommended screening for HCC with at least yearly AFP and abdominal imaging. Rates of HCC screening varied dramatically by etiology of cirrhosis. HCC screening was highest in patients with alcoholic or viral cirrhosis. In contrast, patients with NASH cirrhosis had significantly lower rates of screening (29.7%; p = 0.016) than cirrhotics with viral hepatitis (58.4%), alcoholic cirrhosis (62.5%), or non-viral, non-alcoholic, non-NASH cirrhosis (33.3%) (Fig. 1 ).
HCC Screening Rates Vary by Practitioner Type
We found significant differences in rates of HCC screening based on the type of practitioner involved. Compared to patients seen solely by their primary care physician or surgeon alone, screening was significantly higher in patients referred to a gastroenterologist or hepatologist (58.8 vs. 18.8%; p \ 0.001). The rate of screening increased to 66.7% for those patients who were seen at least once per year by their gastroenterologist compared to those who did not receive regular gastroenterology followup (22.8%; p \ 0.001) (see Table 2 ). Of the patients who were referred for an initial gastroenterology or hepatology consultation, 80% continued to follow-up at least annually.
In addition, patients with NASH cirrhosis were significantly less likely to have received regular gastroenterology or hepatology follow-up (33%) compared to those with viral hepatitis (70%; p \ 0.001), alcoholic (75%; p \ 0.001), or non-viral, non-alcoholic, non-NASH cirrhosis (54%; p = 0.03). They were also less likely to be referred for an initial evaluation by a gastroenterologist or hepatologist (59%) compared to those with viral hepatitis (92.3%) and alcoholic cirrhosis (85%; p \ 0.001 for both) (Fig. 2) .
A subset of 20 patients (13%) was diagnosed with cirrhosis incidentally during a surgical procedure. Patients with incidentally discovered cirrhosis underwent surgery for the following indications: gastric bypass (10), cholecystectomy (5), diverticulitis (1), nephrectomy (1), and Whipple procedure (3). The etiologies of cirrhosis in these specific patients included NASH (n = 11), viral hepatitis (n = 2), alcohol (n = 1), and non-alcoholic, non-viral, non-NASH related liver disease (n = 6). Of this subset, 85% were followed by a primary care physician in addition to a surgeon.
These patients were significantly less likely to receive recommended HCC screening (10.0 vs. 56.6%; p \ 0.001) and were less likely to have either an initial consultation with a gastroenterologist or hepatologist (25 vs. 94%) or regular gastrointestinal subspecialty follow-up (5 vs. 72%) compared to those diagnosed non-surgically (p \ 0.001 for both). When cirrhosis etiology, surgical discovery of cirrhosis, and gastroenterology referral were controlled for in a multivariate analysis, regular follow-up with a gastrointestinal subspecialist was an independent predictor of HCC screening (p \ 0.001), whereas screening in NASH cirrhotics and cirrhotics diagnosed incidentally during surgery appeared dependent on gastroenterology referral. Importantly, while we found that practitioner type influenced screening rates, we found no significant difference in screening based on insurance coverage, race, or gender. Additionally, although patients with viral hepatitis were younger (52.2 years) compared to those with alcoholic (59.2 years), NASH (58.8 years), and non-viral, nonalcoholic, non-NASH cirrhosis (60.5 years), there was no significant difference in screening based on patient age.
When the definition of HCC screening was broadened to include only abdominal imaging not requiring AFP measurements, the overall screening rate rose to 66%, but there continued to be significantly reduced screening in patients with NASH cirrhosis (51%) compared to viral hepatitis (73.8%; p = 0.04) and a trend towards reduced screening compared to alcoholic cirrhosis (65%; p = 0.08). Significantly fewer patients with cirrhosis diagnosed incidentally during surgery and those not regularly seen by a gastroenterologist underwent screening regardless of whether AFP was included as part of a screening protocol (p \ 0.001 for all groups).
Although this study was not powered to detect differences in the rates of hepatocellular carcinoma, of the 156 patients screened over a period of 563 person-years, hepatocellular carcinoma was diagnosed in 14 (2.5%). This incidence was similar to the rates of HCC seen in other studies [3, 10, 16] .
Discussion
This study confirms previous findings that HCC screening practices in cirrhotic patients are suboptimal, with rates comparable to those in previous studies [9, 13, 14] . This study is unique, however, in its evaluation of screening rates by cirrhosis etiology and highlights the suboptimal HCC screening rates in patients with NASH cirrhosis. In addition, to our knowledge, it is one of the first studies to also demonstrate reduced screening in patients whose cirrhosis was diagnosed incidentally during surgery, thus identifying another high-risk group. Although previously thought not to be a significant risk factor for HCC, NASH cirrhosis has recently been shown to have risks for HCC that are comparable to other etiologies of cirrhosis. In a study by Ascha et al. [16] , the yearly cumulative incidence of HCC in NASH cirrhotics was 2.6% compared to 4% in cirrhotics with HCV. Similarly, in a study by Marrero et al. [15] , approximately 29% of cases with HCC were found to be attributable to NAFLD. HCC survival in NASH cirrhosis also appears to be similar to HCC in other forms of cirrhosis [17] . However, despite recent data identifying NASH cirrhosis as an important risk factor for developing HCC, the reduced rate of screening in these patients suggests that awareness of this risk is still lagging. This contention is further supported by the fact that patients with NASH cirrhosis in our study were referred to a gastrointestinal subspecialist significantly less often.
However, our study underscores the importance of gastroenterology and/or hepatology involvement in screening for HCC. Similar to a recent study by Davila et al. [13] that found higher rates of HCC screening in patients seen by a gastroenterologist or hepatologist, our study showed a threefold increase in the rate of HCC screening when patients were referred to a gastroenterologist or hepatologist. Additionally, the reduced screening in NASH cirrhotics and cirrhotics diagnosed incidentally during surgery appears to be directly related to reduced gastroenterology referral, since gastroenterology referral was an independent predictor of HCC screening. The precise mechanism by which gastroenterology or hepatology involvement improves screening is still unclear, but it may reflect not only increased expertise and specialized care but also a greater awareness of cirrhosis complications by the patient's primary care provider rather than solely a direct sub-specialist effect. This is evidenced by the fact that cirrhotics with viral hepatitis and alcoholic cirrhosis were referred to gastrointestinal subspecialists with greater frequency than those with NASH cirrhosis. Although it remains possible that NASH cirrhotics are not referred because of lack of available treatment options, it is more likely that reduced sub-specialist referral in this population reflects reduced awareness of cirrhotic complications in this population. As a case in point, despite the fact that therapies for alcoholic cirrhosis are also not available, these patients were referred more often than those with NASH.
Therefore, future efforts to increase rates of HCC screening in NASH cirrhotics must involve education to primary care physicians. In particular, it should be emphasized that patients with NASH cirrhosis are at equivalent or greater risk for complications of portal hypertension, infection, bleeding, and hepatocellular carcinoma than patients with other forms of cirrhosis. Furthermore, patients with NASH cirrhosis often have additional co-morbidities such as diabetes, obesity, and cardiovascular disease, which may crowd out hepatocellular carcinoma screening in these patients. Nevertheless, given that the average annual risk of hepatocellular carcinoma in cirrhotics with NASH is similar to that of colon cancer and breast cancer in the general population, HCC screening and appropriate subspecialty referral should not be overlooked in patients with NASH cirrhosis [18, 19] .
However, even though gastroenterology and hepatology involvement was associated with improved screening, not all patients seen regularly by gastroenterologists and hepatologists received screening. This suggests that more robust screening of cirrhotic patients for HCC by gastrointestinal subspecialists may require not only recommending screening to primary care providers but also personally directing it.
Systems-based practices may prove useful in improving HCC screening rates. In our study, 13% of patients had their cirrhosis diagnosed incidentally by biopsy during a surgical procedure unrelated to their liver disease. That these patients with surgically discovered disease were not referred to a gastroenterologist or hepatologist and did not receive the recommended screening for HCC suggests that primary care physicians may not be aware of cirrhosis diagnoses made during surgery. This finding is especially important because it may represent a communication gap between multidisciplinary providers. Patients at risk for NASH cirrhosis, particularly those in academic tertiary care health systems, are often cared for by a multidisciplinary team comprised of an internist, a nutritionist, an endocrinologist managing diabetes, and a surgeon managing obesity-related complications. With more patients in such health systems receiving care in a multidisciplinary team, effective communication takes on even greater importance.
Because of this potential communication gap, systemsbased interventions such as automated gastroenterology and primary care physician notifications of all cirrhosis diagnoses made at biopsy, either computer-generated or by other means, may prove beneficial. Automated specialist referral, as seen with infectious disease consultation for inpatients with positive blood cultures, has also shown benefit and improved outcomes and may be effective both in the community and in tertiary care centers [20, 21] . Systems-based notifications and reminders have similarly been shown to increase patient compliance in screening for colon cancer and breast cancer and may be applicable to hepatocellular carcinoma [22, 23] .
As the number of obese patients rises, there will likely be even greater numbers of undiagnosed cirrhotic patients with NASH who will require HCC screening. Furthermore, with increasing data showing the benefits of weightreduction surgery, more cirrhotic patients are likely to be discovered incidentally during surgery and will be at risk for failure to screen [24, 25] . Systems to track information and methods of facilitating communication between primary care physicians, surgeons, gastroenterologists, and hepatologists will therefore be vitally important to take optimal care of this vulnerable population.
Since this study is retrospective, it has limitations. These include a potential selection bias, since those patients who were not seen by gastroenterologists or hepatologists and did not receive recommended HCC screening may represent a group that is less likely to seek subspecialty care or adhere to prescribed therapies than other patients. However, this type of selection bias is likely to be a less significant contributor to our results since patients with NASH were less likely to be seen by gastroenterologists than patients with viral hepatitis or alcoholic cirrhosis, who historically have had more social risk factors associated with poor follow-up. Additionally, while screening of patients with NASH cirrhosis may have been influenced by other obesityrelated co-morbidities to a greater degree than those with viral hepatitis, alcoholic, and non-viral, non-alcoholic, non-NASH cirrhosis, our data suggest that patient age was not significantly associated with HCC screening.
With regard to AFP cut-offs used in screening, receiver operator curve analyses suggest that a value of 20 ng/ml provides the optimal balance between sensitivity and specificity [26] . However, sensitivity at this cut-off is *60% with a positive predictive value of *40%, based on the incidence of HCC seen in most hepatology clinics. AFP values of [200 ng/ml are associated with higher positive predictive values of *60%, but with even less sensitivity. At our institution, a value [20 ng/ml is flagged as abnormal. Since there is likely to be ambiguity amongst both gastroenterologists and primary care physicians as to the appropriate AFP value that necessitates further workup, we chose to set a value [20 ng/ml as the end of our data collection period. Interestingly, at this cut-off, in our cohort only 1 of the 156 patients had their data collection period end on account of an elevated AFP alone. This suggests that despite an AFP cut-off of 20 ng/ml, AFP measurement did not play a significant role in HCC screening in our cohort.
Our study sample was not large enough to assess outcomes of patients who had inadequate screening compared to those who received the recommended screening. However, compared to prior case-control studies investigating HCC screening in patients with diagnosed HCC, this cohort study should be generalizable to cirrhotic patients of many different etiologies who are cared for in variety of practice settings. It should be noted that our study included only those patients with known cirrhosis and does not account for cirrhotics not yet identified, who are likely at even greater risk of failure to screen. Therefore, the rates of screening in our cohort may overestimate the true rates of screening in the general population. Additionally, since patients with NASH cirrhosis often lack both traditional risk factors and serologic markers associated with other types of chronic liver disease, our data may further underestimate the lack of screening among those with NAFLD who are followed exclusively in primary care clinics and may not yet carry a cirrhosis diagnosis. This is significant since our study suggests that HCC screening, even in those with known cirrhosis, occurs less frequently than recommended by professional guidelines.
Lastly, because of limitations of our database, we were unable to differentiate between provider efforts and patient compliance. Are providers not appropriately screening for HCC or are patients not following-up regularly despite a provider's best efforts? Further studies are required to determine the role of specific barriers to patient compliance.
In conclusion, overall rates of HCC screening remain suboptimal and are related to the involvement of gastroenterologists and hepatologists. Importantly, patients with NASH cirrhosis and those diagnosed with cirrhosis incidentally during surgery likely represent a vulnerable group of cirrhotics at even greater risk for failure to screen. Although further prospective study is required, these findings imply that screening awareness may be limited in primary care and surgical practices and that systems-based measures to improve communication between providers are needed. Future studies to evaluate barriers to screening as well as interventions to improve screening are clearly warranted.
